Cargando…

Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types

Despite encouraging results with immune checkpoint inhibition (ICI), a large fraction of cancer patients still does not achieve clinical benefit. Finding predictive markers in the complexity of the tumor microenvironment is a challenging task and often requires invasive procedures. In our study, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Araujo B. de Lima, Vinicius, Hansen, Morten, Spanggaard, Iben, Rohrberg, Kristoffer, Reker Hadrup, Sine, Lassen, Ulrik, Svane, Inge Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027233/
https://www.ncbi.nlm.nih.gov/pubmed/33842304
http://dx.doi.org/10.3389/fonc.2021.558248
_version_ 1783675772719857664
author Araujo B. de Lima, Vinicius
Hansen, Morten
Spanggaard, Iben
Rohrberg, Kristoffer
Reker Hadrup, Sine
Lassen, Ulrik
Svane, Inge Marie
author_facet Araujo B. de Lima, Vinicius
Hansen, Morten
Spanggaard, Iben
Rohrberg, Kristoffer
Reker Hadrup, Sine
Lassen, Ulrik
Svane, Inge Marie
author_sort Araujo B. de Lima, Vinicius
collection PubMed
description Despite encouraging results with immune checkpoint inhibition (ICI), a large fraction of cancer patients still does not achieve clinical benefit. Finding predictive markers in the complexity of the tumor microenvironment is a challenging task and often requires invasive procedures. In our study, we looked for putative variables related to treatment benefit among immune cells in peripheral blood across different tumor types treated with ICIs. For that, we included 33 patients with different solid tumors referred to our clinical unit for ICI. Peripheral blood mononuclear cells were isolated at baseline, 6 and 20 weeks after treatment start. Characterization of immune cells was carried out by multi-color flow cytometry. Response to treatment was assessed radiologically by RECIST 1.1. Clinical outcome correlated with a shift towards an effector-like T cell phenotype, PD-1 expression by CD8+T cells, low levels of myeloid-derived suppressor cells and classical monocytes. Dendritic cells seemed also to play a role in terms of survival. From these findings, we hypothesized that patients responding to ICI had already at baseline an immune profile, here called ‘favorable immune periphery’, providing a higher chance of benefitting from ICI. We elaborated an index comprising cell types mentioned above. This signature correlated positively with the likelihood of benefiting from the treatment and ultimately with longer survival. Our study illustrates that patients responding to ICI seem to have a pre-existing immune profile in peripheral blood that favors good outcome. Exploring this signature can help to identify patients likely to achieve benefit from ICI.
format Online
Article
Text
id pubmed-8027233
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-80272332021-04-09 Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types Araujo B. de Lima, Vinicius Hansen, Morten Spanggaard, Iben Rohrberg, Kristoffer Reker Hadrup, Sine Lassen, Ulrik Svane, Inge Marie Front Oncol Oncology Despite encouraging results with immune checkpoint inhibition (ICI), a large fraction of cancer patients still does not achieve clinical benefit. Finding predictive markers in the complexity of the tumor microenvironment is a challenging task and often requires invasive procedures. In our study, we looked for putative variables related to treatment benefit among immune cells in peripheral blood across different tumor types treated with ICIs. For that, we included 33 patients with different solid tumors referred to our clinical unit for ICI. Peripheral blood mononuclear cells were isolated at baseline, 6 and 20 weeks after treatment start. Characterization of immune cells was carried out by multi-color flow cytometry. Response to treatment was assessed radiologically by RECIST 1.1. Clinical outcome correlated with a shift towards an effector-like T cell phenotype, PD-1 expression by CD8+T cells, low levels of myeloid-derived suppressor cells and classical monocytes. Dendritic cells seemed also to play a role in terms of survival. From these findings, we hypothesized that patients responding to ICI had already at baseline an immune profile, here called ‘favorable immune periphery’, providing a higher chance of benefitting from ICI. We elaborated an index comprising cell types mentioned above. This signature correlated positively with the likelihood of benefiting from the treatment and ultimately with longer survival. Our study illustrates that patients responding to ICI seem to have a pre-existing immune profile in peripheral blood that favors good outcome. Exploring this signature can help to identify patients likely to achieve benefit from ICI. Frontiers Media S.A. 2021-03-25 /pmc/articles/PMC8027233/ /pubmed/33842304 http://dx.doi.org/10.3389/fonc.2021.558248 Text en Copyright © 2021 Araujo B. de Lima, Hansen, Spanggaard, Rohrberg, Reker Hadrup, Lassen and Svane https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Araujo B. de Lima, Vinicius
Hansen, Morten
Spanggaard, Iben
Rohrberg, Kristoffer
Reker Hadrup, Sine
Lassen, Ulrik
Svane, Inge Marie
Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types
title Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types
title_full Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types
title_fullStr Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types
title_full_unstemmed Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types
title_short Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types
title_sort immune cell profiling of peripheral blood as signature for response during checkpoint inhibition across cancer types
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027233/
https://www.ncbi.nlm.nih.gov/pubmed/33842304
http://dx.doi.org/10.3389/fonc.2021.558248
work_keys_str_mv AT araujobdelimavinicius immunecellprofilingofperipheralbloodassignatureforresponseduringcheckpointinhibitionacrosscancertypes
AT hansenmorten immunecellprofilingofperipheralbloodassignatureforresponseduringcheckpointinhibitionacrosscancertypes
AT spanggaardiben immunecellprofilingofperipheralbloodassignatureforresponseduringcheckpointinhibitionacrosscancertypes
AT rohrbergkristoffer immunecellprofilingofperipheralbloodassignatureforresponseduringcheckpointinhibitionacrosscancertypes
AT rekerhadrupsine immunecellprofilingofperipheralbloodassignatureforresponseduringcheckpointinhibitionacrosscancertypes
AT lassenulrik immunecellprofilingofperipheralbloodassignatureforresponseduringcheckpointinhibitionacrosscancertypes
AT svaneingemarie immunecellprofilingofperipheralbloodassignatureforresponseduringcheckpointinhibitionacrosscancertypes